학술논문

Bleeding due to acquired factor V inhibitor successfully treated with platelet transfusion during treatment for recurrent prostate squamous cell carcinoma / 再発前立腺扁平上皮がんの治療中に血小板輸血で止血が得られた後天性第Ⅴ因子インヒビター
Document Type
Journal Article
Source
臨床血液 / Rinsho Ketsueki. 2022, 63(11):1508
Subject
Acquired factor V inhibitor
Platelet factor V
Platelet transfusion
Prostate squamous cell carcinoma
Language
Japanese
ISSN
0485-1439
1882-0824
Abstract
A 78-year-old man with prostate squamous cell carcinoma recurrence in his pelvis was admitted to our hospital. Rectal obstruction led to creation of an artificial anus on the transverse colon. Then, docetaxel and radiation therapies were started. A week later, severe hematuria and melena occurred. Activated partial thromboplastin time (APTT) and prothrombin time (PT) were extremely prolonged. Cross-mixing test for APTT and PT revealed an inhibitor pattern, which was diagnosed as acquired factor V inhibitor. Fresh frozen plasma and vitamin K infusions were ineffective, but platelet transfusion successfully stopped the bleeding. Platelet factor V derived from megakaryocytes may affect local hemostasis. The patient received prednisolone (PSL), and the inhibitor disappeared on day 70 and was in remission. PSL could be stopped on day 100. Later, we demonstrated APTT and PT shortening of factor V deficient plasma by the supernatant of activated platelets with collagen.

Online Access